Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.

Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC.

Blood. 2001 Mar 15;97(6):1885-7.

2.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

3.

[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].

Adam Z, Matýková M, Krejcí M, Pour L, Kissová J, Slechtová M, Chlupová G, Stavarová Y, Simonides J, Penka M, Mayer J, Hájek R.

Vnitr Lek. 2010 Jan;56(1):67-78. Review. Czech.

PMID:
20184115
4.

Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.

Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.

Am J Kidney Dis. 2005 Aug;46(2):270-7. Review.

PMID:
16112045
5.

Primary systemic amyloidosis.

Comenzo RL.

Curr Treat Options Oncol. 2000 Apr;1(1):83-9. Review.

PMID:
12057064
6.

New therapeutic approaches in primary systemic AL amyloidosis.

Sezer O, Eucker J, Schmid P, Possinger K.

Ann Hematol. 2000 Jan;79(1):1-6. Review.

PMID:
10663614
7.

Successful perioperative management of factor X deficiency associated with primary amyloidosis.

Takabe K, Holman PR, Herbst KD, Glass CA, Bouvet M.

J Gastrointest Surg. 2004 Mar-Apr;8(3):358-62. Review.

PMID:
15019934
8.

Autologous stem cell transplantation for primary systemic amyloidosis.

Comenzo RL, Gertz MA.

Blood. 2002 Jun 15;99(12):4276-82. Review.

9.

Primary systemic amyloidosis.

Gertz MA, Rajkumar SV.

Curr Treat Options Oncol. 2002 Jun;3(3):261-71. Review.

PMID:
12057072
10.

Spontaneous rupture of the spleen in AL amyloidosis.

Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V.

Am J Hematol. 2003 Oct;74(2):131-5. Review.

11.

Kidney and liver involvement in monoclonal light chain disorders.

Pozzi C, Locatelli F.

Semin Nephrol. 2002 Jul;22(4):319-30. Review.

PMID:
12118397
12.

Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy.

Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE.

Am J Kidney Dis. 2006 Jun;47(6):947-55. Review.

PMID:
16731289
13.

Managing systemic light-chain amyloidosis.

Comenzo RL.

J Natl Compr Canc Netw. 2007 Feb;5(2):179-87. Review.

PMID:
17335687
14.

Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.

Schönland SO, Dreger P, de Witte T, Hegenbart U.

Bone Marrow Transplant. 2012 Jul;47(7):895-905. doi: 10.1038/bmt.2011.152. Epub 2011 Jul 25. Review.

PMID:
21785469
15.

Therapy for immunoglobulin light chain amyloidosis: the new and the old.

Gertz MA, Lacy MQ, Dispenzieri A.

Blood Rev. 2004 Mar;18(1):17-37. Review.

PMID:
14684147
16.

[Advances in diagnosis and treatment of AL amyloidosis].

Zelichowski G, Lubas A, Wańkowicz Z.

Pol Merkur Lekarski. 2008 Apr;24(142):340-5. Review. Polish.

PMID:
18634370
17.

Factor-X deficiency in amyloidosis: a critical review.

Greipp PR, Kyle RA, Bowie EJ.

Am J Hematol. 1981 Dec;11(4):443-50. Review.

PMID:
7036713
18.

[Diagnosis and treatment in systemic amyloidosis].

Ikeda S.

Rinsho Byori. 2008 Feb;56(2):121-9. Review. Japanese.

PMID:
18404826
19.
20.

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).

Dispenzieri A, Merlini G, Comenzo RL.

Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):6-11. doi: 10.1016/j.bbmt.2007.10.026. Review. Erratum in: Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8.

Supplemental Content

Support Center